A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) (NCT04548999)
A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
Who can join: Review the eligibility criteria below.
Location: Alabama Neurology Associates — Homewood, Alabama
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (147 Sites)
Showing the first 25 of 147 sites.
- Alabama Neurology Associates — Homewood, Alabama
- 21st Century Neurology — Phoenix, Arizona
- University of California Irvine — Irvine, California
- Stanford University Medical Center — Stanford, California
- University of Colorado Denver — Aurora, Colorado
- Advanced Neurosciences Research LLC — Fort Collins, Colorado
- MS and Neuromuscular Center of Excellence — Clearwater, Florida
- University of South Florida — Tampa, Florida
- Baptist Health Lexington — Nicholasville, Kentucky
- International Neurorehabilitation Institute — Lutherville, Maryland
- Massachusetts General Hospital. — Boston, Massachusetts
- University of Massachusetts Medical School — Worcester, Massachusetts
- Michigan Institute for Neurological Disorders — Farmington Hills, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Jersey Shore University Medical Centre — Neptune City, New Jersey
- Northwell Health — Great Neck, New York
- Lenox Hill Hospital — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- Neurology Clinic PC — Cordova, Tennessee
- Advanced Neurosciences Institute — Nashville, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- Lone Star Neurology of San Antonio — San Antonio, Texas
- Texas Institute for Neurological Disorders — Sherman, Texas
- Wheaton Franciscan Healthcare - St. Francis Outpatient Center — Milwaukee, Wisconsin
- CEMIC Saavedra — Buenos Aires,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.